Cargando…

FDA’s Nozzle Numerical Simulation Challenge: Non-Newtonian Fluid Effects and Blood Damage

Data from FDA’s nozzle challenge–a study to assess the suitability of simulating fluid flow in an idealized medical device–is used to validate the simulations obtained from a numerical, finite-differences code. Various physiological indicators are computed and compared with experimental data from th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trias, Miquel, Arbona, Antonio, Massó, Joan, Miñano, Borja, Bona, Carles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965442/ https://www.ncbi.nlm.nih.gov/pubmed/24667931 http://dx.doi.org/10.1371/journal.pone.0092638

Ejemplares similares

The effects of lobbying on the FDA’s recall classification
por: Zhou, Yifan
Publicado: (2023)

Physician Perceptions of the FDA’s Breakthrough Therapy Designation: An Update
por: Paquin, Ryan S, et al.
Publicado: (2022)

Use of the FDA nozzle model to illustrate validation techniques in computational fluid dynamics (CFD) simulations
por: Hariharan, Prasanna, et al.
Publicado: (2017)

LAWS, REGULATIONS, AND POLICY: Genetically Engineered Salmon on the FDA’s Table
por: Taylor, David A.
Publicado: (2010)

The FDA’s Experience with Emerging Genomics Technologies—Past, Present, and Future
por: Xu, Joshua, et al.
Publicado: (2016)

FDA’s tracking and analysis of surveillance sampling isolates for outbreak detection
por: Blessington, Tyann, et al.
Publicado: (2017)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
por: Lee, Sarah, et al.
Publicado: (2023)

Numerical simulation of non-Newtonian flow
por: Crochet, MJ, et al.
Publicado: (1984)

OpenFDA: an innovative platform providing access to a wealth of FDA’s publicly available data
por: Kass-Hout, Taha A, et al.
Publicado: (2016)

COVID-19 emergency responders in FDA’s Center for Drug Evaluation and Research
por: Gormley, Lieutenant Commander Andrea, et al.
Publicado: (2020)

FDA’s Strategies to Close the Health Equity Gap among Diverse Populations
por: Spinner, Jovonni, et al.
Publicado: (2021)

Awareness of and receptivity to FDA’s point-of-sale tobacco public education campaign
por: Dutra, Lauren M., et al.
Publicado: (2023)

Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation
por: Vatsan, Ramjay S, et al.
Publicado: (2013)

Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
por: Kesselheim, Aaron S., et al.
Publicado: (2016)

FDA’s new pharmaceutical quality initiative: Knowledge-aided assessment & structured applications
por: Yu, Lawrence X., et al.
Publicado: (2019)

WITHDRAWN: COVID-19 Emergency Responders in FDA’s Center for Drug Evaluation and Research
por: Gormley, LCDR Andrea, et al.
Publicado: (2020)

A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
por: Niazi, Sarfaraz K.
Publicado: (2023)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
por: Osman, Amira, et al.
Publicado: (2018)

Reporter’s occupation and source of adverse device event reports contained in the FDA’s MAUDE database
por: Kavanagh, Kevin T, et al.
Publicado: (2019)

Can the COVID-19 interstate travel restrictions help lift the FDA’s blood ban?
por: Dorfman, Doron
Publicado: (2020)

The FDA’s Diverse and Dynamic Activities in the Social and Behavioral Sciences: Advancing and Supporting Health Equity
por: Lee, Christine, et al.
Publicado: (2021)

The Food and Drug Administration’s (FDA’s) Drug Safety Surveillance During the COVID-19 Pandemic
por: Diak, Ida-Lina, et al.
Publicado: (2022)

338. ChatGPT Conveys Incorrect Information about the FDA’s Antibiotic Boxed Warnings
por: Linfield, Rebecca, et al.
Publicado: (2023)

Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
por: Mooghali, Maryam, et al.
Publicado: (2023)

Numerical computation of pulsatile hemodynamics and diagnostic concern of coronary bifurcated artery flow for Newtonian and non-Newtonian fluid
por: Uddin, Md. Jashim, et al.
Publicado: (2023)

Numerical Simulation and Experimental Study for the Impact of In-Flow Nozzle on Spray Characteristics
por: Mohamed, Mahmoud Abd El-Aziz, et al.
Publicado: (2021)

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule
por: Kramer, Judith M., et al.
Publicado: (2014)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

Evaluating adverse effects of environmental agents in food: a brief critique of the US FDA’s criteria
por: Vandenberg, Laura N., et al.
Publicado: (2023)

The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
por: Niazi, Sarfaraz K.
Publicado: (2023)

Clinical studies involving probiotics: When FDA’s investigational new drug rubric applies—and when it may not
por: Degnan, Fred H.
Publicado: (2012)

A Primer to the Structure, Content and Linkage of the FDA’s Manufacturer and User Facility Device Experience (MAUDE) Files
por: Ensign, Lisa Garnsey, et al.
Publicado: (2017)

US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
por: Echols, Roger M, et al.
Publicado: (2021)

The FDA’s standard-making process for medical digital health technologies: co-producing technological and organizational innovation
por: Lievevrouw, Elisa, et al.
Publicado: (2021)

Comparison of Newtonian and Non-newtonian Fluid Models in Blood Flow Simulation in Patients With Intracranial Arterial Stenosis
por: Liu, Haipeng, et al.
Publicado: (2021)

Droplet Dynamics of Newtonian and Inelastic Non-Newtonian Fluids in Confinement
por: Ioannou, Nikolaos, et al.
Publicado: (2017)

Corrigendum: Comparison of Newtonian and Non-newtonian Fluid Models in Blood Flow Simulation in Patients With Intracranial Arterial Stenosis
por: Liu, Haipeng, et al.
Publicado: (2021)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
por: Galluppi, Gerald R., et al.
Publicado: (2021)

New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science
por: Chiu, Kimberly, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iqg1utekurprqhav0lv010d7ba